Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

"Artificial Golgi" May Provide New Insight Into Key Cell Structure
Scientists in New York and North Carolina are reporting assembly of the first functioning prototype of an artificial Golgi organelle. That key structure inside cells helps process and package hormones, enzymes, and other substances that allow the body to function normally. The lab-on-a-chip device could lead to a faster and safer method for producing heparin, the widely used anticoagulant or blood thinner, the researchers note. Their study is scheduled for the Aug. 12 issue of the Journal of the American Chemical Society, a weekly publication.

Brain Neural Circuit Formation Requires Identification Of A Key Molecular Pathway
The research group of Dr. Frçİdçİric Charron, a researcher at the Institut de recherches cliniques de Montrçİal (IRCM), has made a discovery which could help treat spinal cord injuries and neurodegenerative diseases. This new finding has been published in the current issue of the prestigious scientific journal Neuron. Patricia T. Yam, Sçİbastien D. Langlois and Steves Morin, all at the IRCM, are listed as co-authors.
News of the day
'Atlastin,' Little-Known Protein, Builds Critical Structures; Does Job In Fundamentally New Way
Italian and U.S. biologists this week report that a little-understood protein previously implicated in a rare genetic disorder plays an unexpected and critical role in building and maintaining healthy cells. Even more surprising, their report in the journal Nature shows that the protein, called "atlastin," does its work by fusing intracellular membranes in a previously undocumented way.
Mental Health

Multiple Myeloma Research Consortium (MMRC) Activates Clinical Trials 30-40 Percent Faster Than Industry Standard

The Multiple Myeloma Research Consortium (MMRC), an innovative research model comprised of a network of 15 academic Member Institutions across North America and leadership in Norwalk, Connecticut, announced preliminary data from an analysis showing that clinical trials opened through its clinical trials network were activated 30 to 40 percent faster than comparable clinical trials in oncology. Based on the implementation of specific business solutions, particularly scientific leadership, standardized clinical contracts and on-site project management res, the MMRC has been able to decrease by an average of 100 days the time from the development and finalization of the trial"s protocol to actual patient enrollment. "This accelerated activation rate may help make myeloma more attractive from a development process as well as de-risk the process for our industry partners," says Susan Kelley, MD, Chief Medical Officer of the MMRC. "With so many new investigational agents in cancer clinical trials and escalating pressures to speed the time to completion of clinical trials, the MMRC is committed to sharing risk with the companies and investigators focused on myeloma to ensure that new treatments are delivered to patients as quickly as possible." "The MMRF and MMRC provide an end-to-end solution for biotech firms and pharmaceutical companies partners seeking to advance promising drug leads into clinical trials," said Susan Molineaux, Ph.D., Founder and Chief Scientific Officer, Proteolix, Inc. who has collaborated with the MMRC to advance two clinical trials through the MMRC"s clinical trials network. "These new data underscore what Proteolix has already experienced in collaborating with the MMRC- speed, efficiency, and results." About the Analysis Data on key activities related to clinical trial start-up were collected and analyzed from 12 Phase I and II clinical trials conducted within the MMRC clinical trials network from May 2006 to March 2009. The analysis demonstrated that the trials initiated during 2007-2008, following the implementation of business solutions were able to open to patient enrollment in an average of 158 calendar days - down from an average of 257 calendar days for trials initiated earlier in the history of the MMRC and consistent with published data about conventional experience with trial activation (Dilts and Sandler, JCO, 2006)). This acceleration represents a 30 to 40 percent time-savings in the rate at which clinical trials were activated. Data will be submitted for presentation at an international scientific meeting later this year. Multiple Myeloma Research Consortium (MMRC)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

İ Copyright 2009